Equities research analysts forecast that Catalyst Biosciences Inc (NASDAQ:CBIO) will announce ($1.05) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Catalyst Biosciences’ earnings. Catalyst Biosciences reported earnings of ($1.15) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 8.7%. The company is expected to report its next earnings results on Thursday, August 6th.
According to Zacks, analysts expect that Catalyst Biosciences will report full-year earnings of ($3.37) per share for the current year, with EPS estimates ranging from ($3.41) to ($3.32). For the next year, analysts anticipate that the firm will report earnings of ($3.54) per share, with EPS estimates ranging from ($4.64) to ($2.43). Zacks’ EPS averages are an average based on a survey of analysts that follow Catalyst Biosciences.
Catalyst Biosciences (NASDAQ:CBIO) last issued its earnings results on Monday, May 11th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.08. The firm had revenue of $16.37 million during the quarter.
Institutional investors and hedge funds have recently modified their holdings of the company. Stonepine Capital Management LLC increased its position in shares of Catalyst Biosciences by 231.7% during the first quarter. Stonepine Capital Management LLC now owns 1,019,196 shares of the biopharmaceutical company’s stock worth $4,454,000 after buying an additional 711,909 shares during the period. Marshall Wace LLP acquired a new position in Catalyst Biosciences in the fourth quarter valued at $855,000. Credit Suisse AG bought a new stake in Catalyst Biosciences during the fourth quarter valued at $688,000. Connor Clark & Lunn Investment Management Ltd. bought a new stake in Catalyst Biosciences during the first quarter valued at $280,000. Finally, Two Sigma Advisers LP grew its holdings in Catalyst Biosciences by 39.2% during the 1st quarter. Two Sigma Advisers LP now owns 193,100 shares of the biopharmaceutical company’s stock worth $844,000 after acquiring an additional 54,400 shares during the period. Institutional investors own 89.11% of the company’s stock.
Shares of NASDAQ:CBIO traded down $0.37 during midday trading on Friday, hitting $5.90. 2,566,609 shares of the stock were exchanged, compared to its average volume of 482,863. The business’s 50-day moving average price is $6.99 and its 200 day moving average price is $6.20. Catalyst Biosciences has a 12 month low of $3.43 and a 12 month high of $9.96. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.13 and a current ratio of 9.13. The stock has a market capitalization of $71.27 million, a price-to-earnings ratio of -1.59 and a beta of 2.39.
About Catalyst Biosciences
Catalyst Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on developing medicines to address hematology indications. Its product pipeline includes marzeptacog alfa, a Factor VIIa variant that is in a Phase II/III clinical trial for the prophylactic treatment of individuals with severe hemophilia A and B with inhibitors.
Further Reading: How To Calculate Debt-to-Equity Ratio
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catalyst Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.